Literature DB >> 8533915

Inhalation toxicity study of a haloalkene degradant of sevoflurane, Compound A (PIFE), in Sprague-Dawley rats.

K A Keller1, C Callan, P Prokocimer, L Delgado-Herrera, M B Friedman, G M Hoffman, W L Wooding, P K Cusick, R W Krasula.   

Abstract

BACKGROUND: Under certain circumstances in the clinical setting, contact of the anesthetic sevoflurane with a CO2 absorbent (e.g., soda lime, Baralyme) leads to the formation of a degradant designated as pentafluoroisopropenyl fluoromethyl ether (PIFE; Compound A). Previous studies have shown that the kidney is the primary target organ for toxicity in the rat. This study was designed to determine the impact of PIFE on rat renal histology correlated with functional changes. The findings are discussed in terms of probable mechanism of action and relevance to humans.
METHODS: Male and female Sprague-Dawley rats were exposed to 0, 30, 61, 114, or 202 ppm PIFE for a single 3-h period via nose-only inhalation. Rats were observed daily for behavioral changes or external physical signs of toxicity (i.e., lacrimation, dyspnea, piloerection, etc.) and body weights were recorded at 6, 4, and 1 day preexposure and 1, 3, 7, and 13 days postexposure. Animals were evaluated for hematologic, clinical chemistry and/or urinalysis changes immediately postexposure and/or at 1, 4, and 14 days postexposure. Rats were killed, subjected to a macroscopic postmortem examination, and evaluated for histopathologic changes in all major tissues and organs at 1, 4, and 14 days postexposure.
RESULTS: Labored breathing was observed in 3 of the 20 and 2 of the 20 rats in the 114 ppm and 202 ppm groups, respectively, during the 3-h exposure period. No significant reductions in body weight gain were noted during the 2-week study period. Clinical chemistry evaluations revealed increases in blood urea nitrogen and creatinine 1 day postexposure in males and females exposed to 202 ppm PIFE. Changes in urinary glucose, protein and N-acetyl-beta-glucoaminidase/creatinine were evident one day postexposure in males and females exposed to 202 ppm and in males exposed to 114 ppm PIFE. Most values were within normal ranges by 4 or 14 days postexposure. No drug-related alterations in hematologic parameters were noted. Evidence of olfactory epithelial degeneration and desquamation in the nasal turbinates was noted at 4 days postexposure in male and female rats exposed to 202 ppm PIFE. Concentration-dependent renal tubular necrosis and tubular cell hyperplasia, in the corticomedullary border, were observed in males and females exposed to 114 and 202 ppm PIFE. The severity of tubular necrosis in both males and females was considered minimal to slight at the 114 ppm exposure concentration and slight to moderate at the 202 ppm exposure. Both the numbers of affected animals and severity were reduced over time. The most marked changes in serum and urine chemistry were associated with the animals described as having moderate renal necrosis. Male rats appeared more susceptible to nephropathy than female rats. There were no other PIFE-related histopathologic findings.
CONCLUSIONS: The renal histopathologic findings in this study are consistent with those reported in previous acute studies in rats after PIFE administration. Functional changes in the kidney, as evidenced by serum chemistry and urinalyses, were observed at exposure concentrations that induced morphologic alterations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8533915     DOI: 10.1097/00000542-199512000-00013

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  16 in total

1.  RE: Yuge O: Renal toxicity of compound A with sevoflurane anesthesia: the benefits of sevoflurane appear to outweight the risks (editorial).J. Anesth 11:1-2.

Authors:  Edmond I Eger; Jackie L Martin
Journal:  J Anesth       Date:  1997-12       Impact factor: 2.078

2.  Humidification during low-flow anesthesia in children.

Authors:  Yuri Nakae; Dai Horikawa; Keiko Tamiya; Akiyoshi Namiki
Journal:  J Anesth       Date:  1998-12       Impact factor: 2.078

Review 3.  Sevoflurance: approaching the ideal inhalational anesthetic. a pharmacologic, pharmacoeconomic, and clinical review.

Authors:  L Delgado-Herrera; R D Ostroff; S A Rogers
Journal:  CNS Drug Rev       Date:  2001

Review 4.  Sevoflurane. A review of its pharmacodynamic and pharmacokinetic properties and its clinical use in general anaesthesia.

Authors:  S S Patel; K L Goa
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 5.  Clinical and economic factors important to anaesthetic choice for day-case surgery.

Authors:  E I Eger; P F White; M S Bogetz
Journal:  Pharmacoeconomics       Date:  2000-03       Impact factor: 4.981

Review 6.  Renal toxicity with sevoflurane: a storm in a teacup?

Authors:  B A Gentz; T P Malan
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 7.  Clinical pharmacokinetics of sevoflurane.

Authors:  M Behne; H J Wilke; S Harder
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

8.  Comparison of the renal safety between carbon dioxide absorbent products under sevoflurane anesthesia: a pilot study.

Authors:  Hyung-Chul Lee; Donguk Kim; Wonsik Ahn; Jiyeon Sim; Yehoon Chung
Journal:  Korean J Anesthesiol       Date:  2012-07-24

Review 9.  Modes of action of trichloroethylene for kidney tumorigenesis.

Authors:  L H Lash; J C Parker; C S Scott
Journal:  Environ Health Perspect       Date:  2000-05       Impact factor: 9.031

10.  Sofnolime with different water content causes different effects in two sevoflurane inhalational induction techniques with respect to the output of compound-A.

Authors:  Shu-jie Liu; Yue Li; Bo Sun; Chang-song Wang; Yu-lei Gong; Yan-mei Zhou; En-you Li
Journal:  Int J Med Sci       Date:  2012-07-25       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.